Carlos L. Arteaga, MD

Carlos L. Arteaga, MD, commented on the findings of the PREFERABLE-EFFECT trial: “This is a wonderful study about what has been obvious to all of us—exercise improves quality of life. Most oncologists probably recommend it, but not necessarily in the structured and rigorous way this study did. We should disseminate and universalize the benefit of this approach for all patients with cancer, including those with metastatic disease.” Dr. Arteaga is Co-Director of the San Antonio Breast Cancer Symposium; Past President of the American Association for Cancer Research; and Director of the Harold K. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, San Antonio. 

DISCLOSURE: Dr. Arteaga has served as a scientific advisor to Novartis, Eli Lilly, Merck, AstraZeneca, Daiichi Sankyo, OrigiMed, Immunomedics, Puma Biotechnology, Taiho Oncology, Sanofi, and Susan G. Komen Foundation; and has received grant support from Pfizer, Eli Lilly, and Takeda.